Chunwei Zhang1,2, Andrew J Tatham1,3, Fábio B Daga1, Alessandro A Jammal1, Felipe A Medeiros4. 1. Visual Performance Laboratory, Duke Eye Center and Department of Ophthalmology, Duke University School of Medicine, 2310 Erwin Rd, Durham, NC, 27710, USA. 2. Department of Ophthalmology, the First Affiliated Hospital, Harbin Medical University, Harbin, China. 3. Princess Alexandra Eye Pavilion and Department of Ophthalmology, University of Edinburgh, Edinburgh, UK. 4. Visual Performance Laboratory, Duke Eye Center and Department of Ophthalmology, Duke University School of Medicine, 2310 Erwin Rd, Durham, NC, 27710, USA. felipe.medeiros@duke.edu.
Abstract
PURPOSE: To investigate the relationship between progression assessed by the visual field guided progression analysis (GPA) and rates of structural and functional change in glaucoma eyes. METHODS: This was a longitudinal observational study of 135 eyes of 97 patients with glaucoma followed for an average of 3.5 ± 0.9 years. All patients had standard automated perimetry (SAP) and retinal nerve fiber layer (RNFL) analysis with spectral domain optical coherence tomography (SDOCT), with an average of 6.8 ± 2.3 visits. A control group of healthy eyes followed longitudinally was used to estimate age-related change. Visual field progression was assessed using the Humphrey Field Analyzer GPA. Estimates of retinal ganglion cell counts from SAP and SDOCT were used to obtain a combined index of glaucomatous damage (RGC index) according to a previously described algorithm. Progression by SDOCT and the retinal ganglion cell (RGC) index were defined as statistically significant (P < 0.05) slopes of change that were also faster than age-related change estimated from healthy eyes. RESULTS: From the 135 eyes, 15 (11%) progressed by GPA, 21 (16%) progressed by SDOCT, and 31 (23%) progressed by the RGC index. Twenty-one eyes showed progression by the RGC index that was missed by the GPA. These eyes had an average rate of change in estimated RGC counts of - 28,910 cells/year, ranging from two to nine times faster than expected age-related losses. CONCLUSION: Many glaucomatous eyes that are not found to be progressing by GPA may actually have fast rates of change as detected by a combined index of structure and function.
PURPOSE: To investigate the relationship between progression assessed by the visual field guided progression analysis (GPA) and rates of structural and functional change in glaucoma eyes. METHODS: This was a longitudinal observational study of 135 eyes of 97 patients with glaucoma followed for an average of 3.5 ± 0.9 years. All patients had standard automated perimetry (SAP) and retinal nerve fiber layer (RNFL) analysis with spectral domain optical coherence tomography (SDOCT), with an average of 6.8 ± 2.3 visits. A control group of healthy eyes followed longitudinally was used to estimate age-related change. Visual field progression was assessed using the Humphrey Field Analyzer GPA. Estimates of retinal ganglion cell counts from SAP and SDOCT were used to obtain a combined index of glaucomatous damage (RGC index) according to a previously described algorithm. Progression by SDOCT and the retinal ganglion cell (RGC) index were defined as statistically significant (P < 0.05) slopes of change that were also faster than age-related change estimated from healthy eyes. RESULTS: From the 135 eyes, 15 (11%) progressed by GPA, 21 (16%) progressed by SDOCT, and 31 (23%) progressed by the RGC index. Twenty-one eyes showed progression by the RGC index that was missed by the GPA. These eyes had an average rate of change in estimated RGC counts of - 28,910 cells/year, ranging from two to nine times faster than expected age-related losses. CONCLUSION: Many glaucomatous eyes that are not found to be progressing by GPA may actually have fast rates of change as detected by a combined index of structure and function.
Entities:
Keywords:
Combined structure function index; Glaucoma progression; Optical coherence tomography; Visual field
Authors: Felipe A Medeiros; Linda M Zangwill; Christopher Bowd; Kaweh Mansouri; Robert N Weinreb Journal: Invest Ophthalmol Vis Sci Date: 2012-10-05 Impact factor: 4.799
Authors: Andrew J Tatham; Robert N Weinreb; Linda M Zangwill; Jeffrey M Liebmann; Christopher A Girkin; Felipe A Medeiros Journal: Invest Ophthalmol Vis Sci Date: 2013-05-07 Impact factor: 4.799
Authors: Felipe A Medeiros; Linda M Zangwill; Douglas R Anderson; Jeffrey M Liebmann; Christopher A Girkin; Ronald S Harwerth; Marie-Josée Fredette; Robert N Weinreb Journal: Am J Ophthalmol Date: 2012-07-27 Impact factor: 5.258
Authors: Christopher Kai-shun Leung; Carol Yim Lui Cheung; Robert N Weinreb; Kunliang Qiu; Shu Liu; Haitao Li; Guihua Xu; Ning Fan; Chi Pui Pang; Kwok Kay Tse; Dennis Shun Chiu Lam Journal: Invest Ophthalmol Vis Sci Date: 2009-08-13 Impact factor: 4.799
Authors: Felipe A Medeiros; Renato Lisboa; Robert N Weinreb; Christopher A Girkin; Jeffrey M Liebmann; Linda M Zangwill Journal: Arch Ophthalmol Date: 2012-09
Authors: Donald C Hood; Sol La Bruna; Emmanouil Tsamis; Ari Leshno; Bruna Melchior; Jennifer Grossman; Jeffrey M Liebmann; Carlos Gustavo De Moraes Journal: Ophthalmol Glaucoma Date: 2022-03-28